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ABSTRAK 
 
Pengenalan: Kanser payudara adalah kanser yang paling biasa di kalangan wanita. Salah 
satu daripada ciri-ciri kanser payudara adalah kaitannya dengan potensi untuk replikasi 
tanpa had oleh sel-sel malignan. Proliferasi selular ini boleh diukur dengan melihat indeks 
pelabelan Ki-67, yang merupakan jenis biomarker percambahan. Kajian ini bertujuan untuk 
membandingkan indeks pelabelan Ki-67 antara manual dan kaedah pengiraan automatik 
dengan pelbagai nilai pemotongan. 
Metodologi: Lapan puluh lapan kanser payudara yang memenuhi kriteria pemasukan dari 
tahun 2014 hingga 2016 telah direkrut dalam kajian ini. Data klinikopatologi telah 
diekstrak daripada laporan patologi. Imunohistokimia untuk Ki-67 telah dilakukan pada 
bahagian-bahagian tisu. Pengiraan manual dan automatik menggunakan perisian 
ImmunoRatio telah dilakukan untuk menilai indeks pelabelan Ki-67. Dua titik pemotongan 
yang berbeza, iaitu <14% dan <20% dipilih. 
Keputusan: Kebanyakan pesakit yang didiagnosis berumur lebih daripada 40 tahun dan 
majoriti adalah orang Melayu. Indeks pelabelan ki-67 dengan pengiraan manual dikaitkan 
dengan kaedah automatik (r = 0.99; p <0.001). Apabila mengubahkan nilai pemotongan 
dari <14% kepada <20%, berbanding dengan kiraan manual, kaedah automatik 
menghasilkan lebih banyak kanser payudara berisiko Luminal B yang diklasifikasikan 
semula ke dalam kanser payudara Luminal A. Menggunakan <20% sebagai titik 
pemotongan, 3 kes yang dinilai sebagai> 20% oleh pengiraan manual diturunkan sebagai 
<20% oleh kaedah automatik. 
xi 
 
Kesimpulan: Kaedah automatik boleh dipercayai dalam menilai kadar percambahan 
dibandingkan dengan kaedah manual, walaupun ada beberapa kes memperlihatkan 
perbezaan antara kedua-dua kaedah tersebut 
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ABSTRACT 
 
Introduction: Breast cancer is the commonest cancer in women. One of the characteristics 
of breast cancer is its association with the limitless replicative potential of the malignant 
cells. This cellular proliferation can be gauged by looking at Ki-67 labelling index, which is 
a type of proliferation biomarker. This study aims to compare the Ki-67 labelling index 
between the manual and the automated counting methods with various cut-off values.  
Methods: Eighty-eight breast cancers that met the inclusion criteria from year 2014 to 
2016 were recruited in this study. Clinicopathological data were extracted from the 
pathology reports. Immunohistochemistry for Ki-67 was performed on tissue sections. 
Manual counting and automated counting using ImmunoRatio software were performed to 
assess the Ki-67 labelling index. Two different cut-off points, i.e. <14% and <20% were 
addressed. 
Results: Most of the patients diagnosed were more than 40 years old and majority 
were Malays. Ki-67 labelling index by manual counting correlated with automated method 
(r=0.99; p<0.001). When shifting the cut-off value from <14% to <20%, as compared to 
manual count, automated method resulted in a larger number of Luminal B breast cancers 
re-classified into Luminal A breast cancers. Using <20% as cut-off point, 3 cases that were 
assessed as >20% by manual counting was downgraded as <20% by automated method.  
Conclusion: The automated method is reliable in assessing proliferation rate as compared 
to the manual method, although a minority of cases showed discrepancy between these two 
methods
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CHAPTER 1 
1.0 INTRODUCTION 
 
Breast cancer is a type of cancer that develops from breast tissue with several symptoms, 
which may include a breast lump, deformation of breast shape, skin dimpling, nipple 
discharge, or erythematous skin changes (Rathnam, 2012). According to MALAYSIAN 
NATIONAL CANCER REGISTRY REPORT 2007-2011 (MNCRR), a total of 64,275 
cancer deaths, either medically certified or non-medically certified, were reported by the 
National Registration Department in the period of year 2007 to 2011;  breast cancer 
emerged as the most common cancer among female. 
Enabling replicative immortality is one of the hallmarks of cancer; it enables the cell to 
proliferate uncontrollably without any limit.  In breast cancer, accumulation of mutations 
in various genes that control cell proliferation ultimately leads to cell growth and cell 
division.  The resultant cells will no longer respond to the many inhibitory signals for 
cellular growth and death (Fagagna, 2007). To glimpse into this hallmark of cancer, 
proliferation rate of breast cancer can be measured via an immunohistochemical staining 
method to measure the percentage of tumor cells that are positive for Ki-67. Ki-67 is a 
nuclear protein and represents cellular marker for proliferation: this protein increases as 
the cells prepare to divide. This protein exits in all active phases of cell cycle (G1, S, G2, 
and mitosis), however, is not detected from the resting cells (G0) (Ronell Bologna-
Molina, 2013). 
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Measurement of proliferation rate by Ki-67 labeling index can be performed via visual 
counting of positively stained nuclei under microscope. Recently, image analyzed Ki-67 
assessment has also been reported in several studies (Fangfang Zhong, 2016) (Gustav 
Stålhammar, 2016). Therefore, this study is conducted to compare these two methods of 
assessment of Ki-67 labelling index, and to assess how the results would impact on 
further classification of breast cancer in term of molecular subtypes, which would have 
different prognostic significance. 
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CHAPTER 2 
2.0  LITERATURE REVIEW 
2.1 Breast Cancer 
 
Breast cancer is a type of cancer that develops from breast tissue with several symptoms, 
which may include a breast lump, deformation of breast shape, skin dimpling, nipple 
discharge, or erythematous skin changes (Rathnam, 2012). Of those with distant spread, 
the patients may suffer from bone pain, lymphadenopathy, shortness of breath, or 
jaundice (Christobel Saunders, 2009). According to world cancer report 2014,  risk 
factors for developing breast cancer are many; well established risk factors include being 
female, obesity, alcohol consumption, lack of physical exercise, hormone replacement 
therapy, past exposure to radiation, early age at menarche, having children late or 
nulliparous, older age, and a past family history of breast cancer (Breast Cancer, 2014). 
Breast cancer usually refers to malignant transformation of epithelial cells of the lobules 
and ducts of milk-producing glands and associated passages draining the milk to the 
nipple; at a much rarer rate, malignant transformation of the stroma tissues such as fatty 
and fibrous connective tissues of the breast also occurs. (K. Narayanasamy, 2014). 
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2.2 Epidemiology of Breast Cancer 
 
K McPherson et al. (2000) reported that breast cancer is the commonest cancer in 
women, comprising 18% of all female cancers (K McPherson, 2000). According to 
GLOBOCAN 2012, 14.1 million new cancer cases and 8.2 million cancer deaths were 
estimated in 2012 worldwide (Figure 2.1a and 2.1b), whereby breast cancer appears as 
the second most common cancer in the world. It is also the most frequent cancer among 
women; in 2012, an estimated 1.67 million new cancer cases were diagnosed, which 
comprised about 25% of all cancers. It is the most common cancer diagnosed in both 
developing and developed regions (Figure 2.2a and 2.2b); more cases were documented 
in less developed (883,000 cases) than in more developed regions (794,000) (Jacques 
Ferlay, 2015).  
In Malaysia, the census population of Peninsular Malaysia in 2016 was 31.7 million. A 
total number of 103,507 new cancer cases were diagnosed in Malaysia during the period 
of year 2007 to 2011 (Table 2.1) whereby 46,794 (45.2%) occurred in males and 56,713 
(54.8%) in females (Azizah Ab Manan, 2015). According to MALAYSIAN 
NATIONAL CANCER REGISTRY REPORT 2007-2011 (MNCRR), a total of 64,275 
cancer deaths, either medically certified or non-medically certified, were reported by the 
National Registration Department of in the period of year 2007 to 2011; breast cancer 
was the most common cancer among female, recording 18,206 (32.1%) cases (Table 
2.2); it was also the most common cancer in the population regardless of sex in Malaysia  
(Azizah Ab Manan, 2015). 
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Figure 2.1a and 2.2b: Estimated new cases and deaths worldwide with 
proportions by world regions for both sexes, 2012. The area of the pie is proportional to 
the number of new cases or deaths. Adapted from GLOBOCAN 2012 
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Figure 2.2a and 2.2b: Estimated new cancer cases (incidence) and deaths 
(mortality) in thousands in more developed and less developed regions of the world 
among females in 2012. Adapted from GLOBOCAN 2012 
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Table 2.1: Ten most common cancers among all residents in Malaysia, 2007-2011. 
Adapted from MNCRR 
Icd-10 Sites Number % 
C50 Breast 18,343 17.7 
C18-C21 Colorectal 13,693 13.2 
C33-C34 Trachea, Bronchus, 
Lung 
10,608 10.2 
C81-C85, C96 Lymphoma 5,374 5.2 
C11 Nasopharynx 5,090 4.9 
C91-C95 Leukaemia 4,573 4.4 
C53 Cervix Uteri 4,352 4.2 
C22 Liver 4,128 4.0 
C56 Ovary 3,472 3.4 
C16 Stomach 3,461 3.3 
 Others 30,413 29.4 
 Total 103,507 100.0 
 
 
Table 2.2: Ten most common cancers in Malaysia among female residents, 2007-
2011. Adapted from MNCRR 
Icd-10 Sites Number % CR ASR 
C50 Breast 18,206 32.1 28.6 31.1 
C18-C21 Colorectal 6,047 10.7 9.5 11.1 
C53 Cervix uteri 43,52 7.7 6.8 7.6 
C56 ovary 3,472 6.1 5.4 5.9 
C33-c34 Trachea, 
bronchus, lung 
3,193 5.6 5.0 6.0 
C81-c85, 
c96 
Lymphoma 2,203 3.9 3.5 3.8 
C54 Corpus Uteri 2,181 3.8 3.4 3.8 
C91-95 Leukaemia 2,024 3.6 3.2 3.4 
C73 thyroid 1,723 3.0 2.7 2.9 
C16 Stomach 1,447 2.6 2.3 2.6 
 Others 11,865 20.9   
 Total 56,713 100.0 89.0 99.3 
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2.2 The Hallmarks of Cancer 
 
In early 2000, Douglas Hanahan and Robert A. Weinberg proposed the concept - the 
hallmarks of cancer - that comprises six biological capabilities, which are acquired 
during the multistep carcinogenesis. This proposal constitutes an organized principle to 
reasonably understand the complexities of neoplastic disease (Figure 2.3).  The 
hallmarks of cancer are summarized as (i) sustaining proliferative signaling, (ii)evading 
growth suppressors, (iii) resisting cell death, (iv)enabling replicative immortality, 
(v)inducing angiogenesis, and (vi) activating invasion and metastasis, which are 
ubiquitous in most and perhaps all types of human tumors (Douglas Hanahan, 2011). 
Later in 2011, an updated concept by Douglas Hanahan and Robert A. Weinberg 
(Hallmarks of Cancer: The Next Generation) proposed four additional hallmarks of 
cancer (Figure 2.4). These four hallmarks are recognized as (vii) deregulation cellular 
energetics, (viii) avoiding immune destruction, (ix) genome instability and mutation, and 
(x) tumor-promoting inflammation (Douglas Hanahan, 2011). 
 
 
 
 
 
 
9 
 
 
 
 
 
 
Figure 2.3: The hallmarks of cancer: six biological acquired capabilities of cancer as 
originally proposed. Adapted from (Douglas Hanahan, 2011). 
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Figure 2.4: The four additional hallmarks of cancer: the emerging hallmarks and 
enabling characteristics. Adapted from (Douglas Hanahan, 2011). 
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2.3 Enabling Replicative Immortality 
 
Among the hallmarks of cancer, enabling replicative immortality is probably the most 
important hallmark. Hayflick in the early works has shown that cells in culture have a 
finite replicative potential (Hayflick, 1997). After progression through a certain number 
of doublings, such cell populations will stop growing. This process has been termed as 
senescence. In cultured human fibroblasts, the process of senescence can be 
circumvented by inactivation of their pRb and p53 tumor suppressor proteins; this will 
enable these cells to continue to multiply for additional generations; they will then enter 
into a second state called crisis (Douglas Hanahan, 2000).  According to Wright et al., 
the crisis state is characterized by massive cell death, karyotypic disarray that is 
associated with end-to-end chromosomal fusion, and the occasional emergence of an 
advantageous variant in the rate of 1 in 107 cells. This variant of cells has acquired the 
ability to multiply without limit, the trait termed as immortalization (Wright, 1989). 
Hayflick articulated that most types of tumor cells that are propagated in culture appear 
to be immortalized. This immediately implies that during tumor progression, limitless 
replicative potential is a trait that is acquired in vivo, thus is basically essential for the 
development of malignancy. (Hayflick, 1997). Multiple lines of evidence indicate that 
the capability for unlimited proliferation is made possible by telomeres that protect the 
ends of chromosomes (Blasco, 2005) (Shay, 2000). 
Telomeres are located the end of chromosomes that have a special structure. They 
protect the ends of chromosomes from fusion, recombination, or being recognized as 
12 
 
uncapped DNA breaks (Harley, 1991) (Blackburn, 2001). However, with each cycle of 
cell division, telomeres shorten due to the end replication problem in linear 
chromosomal DNA. Critically shortened telomeres fail to protect the chromosome ends. 
This will trigger the DNA damage response leading to cellular senescence or apoptosis 
(Kyotaro Hirashima, 2013). In tumor cells, this problem is resolved as there is a 
mechanism whereby reactivation of the reverse transcriptase termed telomerase could 
stabilize the telomere length. Telomerase is unique in structure as it is composed of a 
RNA component (hTR or hTERC) (Kelland, 2007) and a catalytic protein (hTERT) 
(Blackburn EH, 2006). In addition, human telomeric DNA is associated with a group of 
proteins (at least six proteins to date), collectively termed shelterin. TRF1 and TRF2 of 
shelterin bind to double-stranded telomeric DNA; POT1 in shelterin binds the single-
stranded 3ˊ G-rich overhang; three interconnecting proteins (TIN2, TPP1, and RAP1) act 
to shape and safeguard telomeres (Wang F, 2007). 
 
2.4 Ki-67 
 
Related to this hallmark of enabling replicative immortality, cell proliferation is one of 
cellular aspect that could be easily observed and measured.  In cancer, cell proliferation 
constitutes one of the most important prognostic factors and it relates to overall patient 
survival (Aleskandarany MA, 2010) (Dai H, 2005). There are a number of biomarkers 
associated with proliferation; Ki-67 is regarded as the most suitable candidate for breast 
cancer research as this protein is expressed in all the phases of the cell cycle except G0, 
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either in normal or malignant cells.  Ki-67 assessment is an easy and reliable method of 
assessing the cell cycle pathway (Rumiko Tashima, 2015). Ki-67 has been identified as a 
nuclear antigen associated with cell proliferation since 1983 (Gerdes J, 1983),   and 
considerable enthusiasm has been poured to employ Ki-67 assessment in studies. 
Although the protein’s structure and properties are now greatly elucidated, its functional 
role remains elusive (Xue-Qin Yang, 2011). 
 
2.5  Molecular Subtypes of Breast Cancer  
 
With the advent of genomic research, breast cancers have been discovered to constitute 
several distinct diseases based on gene expression profiling, termed as molecular 
subtypes of breast cancer. Using a number of immunohistochemically available 
surrogate markers, these molecular subtypes could be considerably reproduced without 
more sophisticated gene expression profiling.  Cheang et al. classified breast cancers into 
Luminal A, Luminal B, Her-2-overespressed, and triple negative breast cancer by 
employing a panel of biomarkers comprised of estrogen receptor, progesterone receptor, 
Her-2, and Ki-67 labelling index. They proposed a 14% cutoff value for Ki-67 labelling 
index.  Hormone receptor–positive breast cancers having Ki-67 < 14% are classified as 
Luminal A and those with ≥ 14% as Luminal B breast cancer. This results in comparable 
molecular subtypes with gene expression profiling method (Cheang MC, 2009). In 
addition, baseline Ki-67 labelling index has been found to be higher in triple negative 
breast cancers that do not express ER, PR and HER2 (Bhumsuk Keam, 2011), whereas 
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ER positive and/or PR positive breast cancers have a lower Ki-67 labelling index (Trihia 
H, 2003). Furthermore, in the 2011 and in the 2013 St Gallen Consensus Conference, 
Ki-67 labeling index was recommended for the determination of proliferation. This piece 
of information forms the criterion to differentiate Luminal A and Luminal B breast 
cancers   (Gnant M, 2011) as pioneered by Perou et al.; the study by Perou et al. was the 
first in demonstrating the presence of so-called intrinsic molecular breast cancer 
subtypes (Perou CM, 2000). Table 2.3 shows breast cancer subtypes as recommended by 
the panel of experts at the St Gallen Consensus (Goldhirsch A, 2013). 
 
Table 2.3: Breast cancer subtypes. Source: (Goldhirsch A, 2013). 
Breast cancer Definition 
Luminal A ER positive, PR positive, HER2 negative 
Ki-67 index low (defined as <14% 
Luminal B Luminal B (HER2 negative) 
ER positive, HER2 negative and one of: 
Ki-67 index high (defined as 14% and 
above) 
PR negative or low (defined as <20%) 
Luminal B (HER2 positive) 
ER positive, HER2 over-expressed or 
amplified, any ki-67 index, any PR 
HER2 over-expressing HER2 over-expressed or amplified, ER 
and PR negative 
Triple negative ER and PR negative, HER2 negative 
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2.6 Assessment of Ki-67 
 
The fundamental of assessment of Ki-67 labelling index is estimation of proportion of 
positively-stained tumor cell nuclei for Ki-67 protein by immunohistochemistry. 
Compared to other markers of proliferation, Ki-67 labelling index as such measured is 
accurate, easy and cost-efficient; its staining and assessment are consistent. Therefore 
Ki-67 labeling index is deemed an ideal diagnostic tool (Urruticoechea A, 2005). In 
2011, the International Ki-67 in Breast Cancer Working Group proposed guidelines for 
the analysis, reporting, and use of Ki-67. These guidelines aimed to reduce inter-
laboratory variability; this would lead to improvement of inter-study comparability of 
Ki-67 results; however, firm recommendations for best practice could not be put forward 
due to limited evidence (Mitch Dowsett, 2011). 
 
Visual assessment (VA) at a glance has been widely championed to evaluate Ki-67 
labeling index in a considerable number of pathological institutions and laboratories due 
to its ease; nonetheless there are limitations, for instance, the reproducibility of 
intermediate Ki-67 labelling index is relatively poor. Of importance, Ki-67 labelling 
index in such situation, especially in the moderately differentiated (tumor grade 2) breast 
cancers, is critical for clinical decisions (Vörös A, 2013) (Gudlaugsson E, 2012).  
 
To partly address this problem of reproducibility, recently, image analysis techniques 
have been introduced; this offers the potential for automated assessment and also better 
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precision in assessment. Heterogeneity in breast cancer remains one of the unsolved 
issues in this kind of assessment (Urruticoechea A, 2005). 
 
2.7  Ki-67 labeling index: technicalities  
 
Chung YR et al. in the article ‘Interobserver Variability of Ki-67 Measurement in Breast 
Cancer’ has rightly pointed out several methodological issues concerning Ki-67 labeling 
index interpretation that lead to variability in its measurement (Yul Ri Chung, 2016).  
Firstly, the assessment is observer-dependent; the areas selected for counting and the 
number of tumor cells counted may be different for each observer. Secondly, it is the 
intrinsic nature of cancer that the breast cancers may exhibit intra-tumoral heterogeneity 
in cell proliferation with areas showing more intense staining of Ki-67; these intensely 
stained areas are known as “hot spots”. Thirdly, manual counting or digital image 
analysis of Ki-67 labelling index depends on institutional preference. Lastly, Ki-67 
labelling index maybe reported in continuous numbers whereas others may record this 
index in categorical values with various cutoff values (Yul Ri Chung, 2016). 
Acknowledging these technicalities, this study aims to address the issue of manual count 
versus automated count methods. Different cutoff values will be tested to assess the 
impact of Luminal breast cancer subtyping.  
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CHAPTER 3 
3.0 OBJECTIVE OF STUDY 
3.1 General Objective 
 
A retrospective study of a center experience in assessing proliferation index of breast 
cancer by Ki-67 labeling index 
 
3.2 Specific Objective 
 
The specific objectives of this study are 
a) To assess Ki-67 labeling index by (i) manual counting and (ii) automated 
counting by image analysis  software (ImmunoRatio) 
b) To compare the results of Ki-67 labeling index between these two methods. 
c) To assess the molecular subtyping of breast cancer based on ER, PR, Her-2, 
CK5/6 and Ki-67 labeling index obtained from these two methods. 
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CHAPTER 4 
4.0 METHODOLOGY 
4.1 Study Design and Ethical Approval 
 
This was a retrospective study with review of pathology reports and histopathology 
slides from the year 2014 to 2016 for breast cancer cases reported in Advanced Medical 
and Dental Institute (AMDI), Universiti Sains Malaysia. Ethical approval was obtained 
prior to commencement of this study from Human Research Ethics Committee, USM 
(HREC) with the approved study protocol code: USM/JEPeM/16120538.  
 
4.2 Study Sample 
 
Archived histopathology slides and corresponding paraffinized tissue blocks from breast 
cancer mastectomy specimens in the Histopathology and Cytology unit, Advanced 
Diagnostic Laboratory, Advanced Medical and Dental Institute (AMDI), Universiti 
Sains Malaysia, from the year 2014 to 2016 were retrieved for this study. The specimens 
had been examined by pathologists of Histopathology and Cytology unit and formal 
pathology reports had been issued within the stated period. 
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4.3 Sample Size 
 
This was a pilot study. Eighty-eight cases were obtained from archive that met the 
following inclusion criteria. 
 
4.4 Inclusion Criteria 
 
All invasive breast cancer surgical specimens (lumpectomy, wide local excision or 
mastectomy) for the year 2014 to 2016 were included in this study. 
 
4.5 Exclusion Criteria 
 
Cases that fulfilled the inclusion criteria but the histopathology slides and/or 
corresponding paraffinized tissue blocks that were unavailable, missing, or inadequate 
for serial sections were excluded from this study. Pure in situ breast cancer was also 
excluded. 
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4.6 Retrieval of Pathology Report and Clinicopathological Data 
 
Clinicopathological data of interest for each case were retrieved from archived formal 
pathology reports. The data of interest were age, gender, laterality, tumor grade, mitotic 
rate/10HPF, presence of lymphovascular invasion, tumor pathological stage, 
pathological stage of lymph node metastasis, tumor size, number of nodal metastasis, 
number of retrieved lymph nodes, presence of ductal carcinoma in situ (DCIS) 
component, estrogen and progesterone receptor status, Her-2 expression status, CK 5/6 
status and Ki-67 labeling index (manual counting). 
 
4.7 Patient Confidentiality 
 
In order to protect patients’ confidentiality, tissue block/slide and clinicopathological 
data retrieved from each case remained confidential by masking the personal data with 
the laboratory numbers. Data analysis was referred solely to the laboratory numbers. 
 
4.8 Immunohistochemistry for Ki-67 
 
To obtain Ki-67 labeling index, a section from each case was immunostained with 
antibody against Ki-67 protein. The immunohistochemistry for Ki-67 is outlined as 
follows: 
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(a) Dewax and Hydrate: After tissue was sectioned and mounted, it was placed on hot 
plate for at least 60 minutes to facilitate adherence. Dewax was performed by immersion 
in xylene with two changes for 2 minutes each and followed by two changes of absolute 
alcohol for 2 minutes each. The tissue section was gradually hydrated in 95%, 80%, 70% 
and 50% alcohol for 2 minutes each and lastly, tissue section was washed thoroughly in 
distilled water for 2 changes. 
(b) Staining: Tissue section was immersed in Target Retrieval Solution (Tris-EDTA 
buffer, pH 9.0) and heated in pressure cooker for at least 20 minutes. After that, tissue 
section was cooled in running tap water for 20 minutes.  The section was then rinsed 
with TBS (pH 7.6) before it was treated with 120 µl of Peroxidase Blocking Solution for 
5 to 10 minutes. Then, the section was once again rinsed with TBS (pH 7.6) for three 
times before it was incubated with primary antibody (MIB-1, Dako)   of 200 µl per 
section (dilution of 1: 150) for 1 hour.  The section was rinsed with TBS (pH 7.6) for 
four times or more. It was then incubated with secondary antibody for 30 minutes. 
Tissue section was rinsed once with TBS (pH 7.6) and distilled water. Excess distilled 
water around the section was wiped off. It was then incubated with DAB (3, 3′-
Diaminobenzidine) substrate 1ml : 1 drop (DAB + substrate : DAB + Chromogen) for 10 
minutes. Next, the section was placed under running tap water for a few seconds and 
counter-stained in Hematoxylin for 1 minute. Lastly it was placed under running tap 
water for 1 minute. 
(c) Dehydrate and Clearing: The tissue section was dehydrated by dipping in 80% 
alcohol 10 times and followed by dipping in two changes of 95% alcohol 10 times. Next, 
the section was immersed in absolute alcohol with three changes for 2 minutes each. 
